NASDAQ$IRMD
IRadimed Corporation · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
IRadimed reported record high total bookings and revenue growth trends, overcoming challenges from the past year.
IRadimed Corporation announced financial results for Q2 2021, with revenue of $9.8 million compared to $6.8 million for Q2 2020. Net income was $1.5 million, or $0.12 per diluted share, compared to a net loss of $(2.1) million, or $(0.17) per diluted share for Q2 2020. Non-GAAP net income was $1.7 million, or $0.14 per diluted share, compared to $0.6 million, or $0.05 per diluted share for Q2 2020.
- Reported revenue of $9.8 million, an increase from $6.8 million in Q2 2020.
- Achieved net income of $1.5 million, or $0.12 per diluted share, compared to a net loss of $(2.1) million, or $(0.17) per diluted share in Q2 2020.
- Non-GAAP net income reached $1.7 million, or $0.14 per diluted share, compared to $0.6 million, or $0.05 per diluted share in Q2 2020.
- Domestic sales accounted for 82.0% of total revenue, compared to 68.3% in Q2 2020.
Headline financials
Revenue & EPS history
IRadimed · Revenue · Quarterly
$9.81M
Forward guidance
For the third quarter 2021, the Company expects to report revenue of $10.3 million to $10.5 million, GAAP diluted earnings per share of $0.14 to $0.15, and non-GAAP diluted earnings per share of $0.16 to $0.17. For the full year 2021, the Company expects to report revenue of $40.0 million to $40.4 million, GAAP diluted earnings per share of $0.53 to $0.55, and non-GAAP diluted earnings per share of $0.60 to $0.62.
Tailwinds
- Expects to report revenue of $10.3 million to $10.5 million for Q3 2021.
- GAAP diluted earnings per share of $0.14 to $0.15 for Q3 2021 expected.
- Non-GAAP diluted earnings per share of $0.16 to $0.17 for Q3 2021 expected.
- Expects to report revenue of $40.0 million to $40.4 million for full year 2021.
- GAAP diluted earnings per share of $0.53 to $0.55 for full year 2021 expected.
Headwinds
- Non-GAAP diluted earnings per share guidance excludes stock-based compensation expense, net of tax.
- Stock-based compensation expense expected to be approximately $0.3 million for Q3 2021.
- Stock-based compensation expense expected to be approximately $1.1 million for full year 2021.
- Guidance is based on information available to the company on the date of the report.
- Guidance is subject to risks and uncertainties.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
+2.2%
Avg return
Earnings day
+2.0%
Avg return
5 days after
+2.8%
Avg return
30 days after
59%
30 / 51 earnings
Positive
+32.1%
Q2 2019
Best reaction
-20.0%
Q1 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.5% | +3.4% | +8.6% | |
| Q4 2025 | +9.6% | +4.0% | +3.5% | |
| Q3 2025 | +9.4% | +9.8% | +21.3% | |
| Q1 2025 | -2.3% | -3.0% | +13.7% | |
| Q4 2024 | -8.4% | -5.8% | -13.3% | |
| Q3 2024 | -8.8% | -0.4% | +1.9% | |
| Q2 2024 | -4.9% | -6.6% | +0.5% | |
| Q1 2024 | +6.4% | +4.0% | +1.1% | |
| Q4 2023 | -6.9% | -3.3% | -5.2% | |
| Q3 2023 | +3.5% | -1.3% | +3.5% | |
| Q2 2023 | +10.7% | +10.4% | +9.7% | |
| Q1 2023 | +8.5% | +8.3% | +13.0% | |
| Q4 2022 | +10.1% | -0.3% | +3.7% | |
| Q3 2022 | +5.2% | +6.0% | +9.4% | |
| Q2 2022 | -1.4% | -3.2% | -17.8% | |
| Q1 2022 | -17.2% | -21.5% | -19.4% | |
| Q4 2021 | +19.8% | +33.5% | +24.1% | |
| Q3 2021 | +6.4% | +5.1% | +16.8% | |
| Q2 2021 | +1.0% | -1.8% | -2.2% | |
| Q1 2021 | +5.9% | +9.2% | +3.9% | |
| Q4 2020 | -7.2% | -2.4% | -7.8% | |
| Q3 2020 | +3.1% | +2.7% | +9.0% | |
| Q2 2020 | -4.2% | -2.7% | -7.2% | |
| Q1 2020 | -7.9% | -8.4% | +8.1% | |
| Q4 2019 | +2.4% | -0.5% | -10.8% | |
| Q3 2019 | +5.5% | +1.9% | -8.2% | |
| Q2 2019 | +32.1% | +23.6% | +7.1% | |
| Q1 2019 | -20.0% | -15.1% | -25.3% | |
| Q4 2018 | -0.4% | -0.9% | -12.4% | |
| Q3 2018 | +1.7% | +4.8% | +16.1% | |
| Q2 2018 | +4.6% | +9.8% | +17.5% | |
| Q1 2018 | +13.6% | +15.1% | +17.0% | |
| Q4 2017 | -6.3% | -7.3% | -13.6% | |
| Q3 2017 | +12.2% | +7.1% | +11.0% | |
| Q2 2017 | +17.3% | +14.9% | +18.5% | |
| Q1 2017 | -3.4% | -3.4% | -6.2% | |
| Q4 2016 | -4.0% | -2.8% | -2.8% | |
| Q3 2016 | +2.2% | +0.5% | +22.7% | |
| Q2 2016 | +2.8% | -4.6% | -1.2% | |
| Q1 2016 | -5.6% | — | — | |
| Q4 2015 | -17.1% | — | — | |
| Q3 2015 | +11.6% | — | — | |
| Q1 2014 | +0.2% | — | — | |
| Q2 2015 | +18.6% | — | — | |
| Q1 2015 | +2.2% | — | — | |
| Q4 2014 | +7.2% | — | — | |
| Q3 2013 | +4.9% | — | — | |
| Q3 2014 | +4.9% | — | — | |
| Q4 2013 | -2.3% | — | — | |
| Q2 2013 | -2.3% | — | — | |
| Q2 2014 | -0.4% | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro